Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Uncontrolled study (n=344) found that lisocabtagene maraleucel, an autologous, CAR T-cell product, achieved an objective response in 74%, and a complete response in 53% of patients. Cytokine release syndrome and neurological events occurred in 42% and 30% patients, respectively.


The Lancet